Inventiva (NASDAQ:IVA) (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies. In addition to lanifibranor, Inventiva is advancing IVA337-related programs and novel small molecules targeting rare diseases such as fibrodysplasia ossificans progressiva (FOP). The pipeline is supported by proprietary chemistry and pharmacology capabilities that enable the optimization of drug candidates with improved efficacy and safety profiles.
Headquartered in Daix, France, Inventiva conducts clinical development activities across Europe and North America. The company collaborates with academic institutions, contract research organizations and strategic partners to support clinical trial conduct and regulatory interactions. Inventiva’s integrated research and development infrastructure includes laboratories in Dijon and a U.S. subsidiary to facilitate patient recruitment and regulatory filings in the United States.
Founded in 2012 as a spin-off from French academic research, Inventiva has built a management team with extensive experience in drug discovery and clinical development. Philippe Luscan, Pharm.D., serves as Chief Executive Officer and has been instrumental in steering the company through its initial public offerings on Euronext Paris and Nasdaq. Under his leadership, Inventiva continues to pursue innovative therapies aimed at addressing significant unmet medical needs in chronic and rare diseases.
